Brief: Pharmacyte Biotech Receives U.S. FDA Clinical Hold Letter
04/11/2020 14:30
Nov 4 (Reuters) - PharmaCyte Biotech Inc PMCB.PK :
* PHARMACYTE BIOTECH RECEIVES U.S. FDA CLINICAL HOLD LETTER
* PHARMACYTE BIOTECH INC - FDA HAS INFORMED COMPANY THAT IT
NEEDS
TO CONDUCT SEVERAL ADDITIONAL PRECLINICAL STUDIES.
* PHARMACYTE BIOTECH - FDA REQUESTED ADDITIONAL INFORMATION
REGARDING SEVERAL TOPICS,INCLUDING DATA, MANUFACTURING, PRODUCT
RELEASE SPECIFICATION
Source text for Eikon: ID:nBwbqMGV7a
Further company coverage: PMCB.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer